Εκπαιδευτικά προγράμματα
Λίστα αντικειμένων

Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Lekka, Dr Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Lekka, Dr Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Lekka, Dr Vadratsikas


A retrospective analysis of PTCY vs ATG performed form ALWP
of EBMT and contribution of our team.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Lekka, Dr
Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Lekka, Dr Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Lekka, Dr Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Lekka, Dr Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Lekka, Dr
Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Lekka, Dr Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Lekka, Dr Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Lekka, Dr Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Lekka,Dr Vadratsikas


Our institutional guidelines discussed
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


The first successful trial in steroid refractory GVHD.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


We discussed a case of CNS lymphoma and the diffrent HD
regimens.
we favour regimens with Rituxmab, Thiotepa and bu or AraC
R-Busulfan-thiotepa Rituximab -6 Busulfan 2 days -5, -4
Thiotepa 5 mg/kg days -4 and -3
(https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5473-z)
Other regimens
Regimen without Thiotepa
BUCYE Busulfan 3.2 mg/kg days...


We discussed the current EBMT guidelines for COVID19.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


The current Indications for HCT were discussed.
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


This cohort analysis evaluates theincidence, risk factors and
mortality of pre-engraftment blood-stream infections(BSIs) and
ds-DNAviral infections (VIs) after HSCTwith post-transplant
cyclophosphamide(PT-Cy) platform among different donor
sourcesAllogeneic HSCT with PT-Cy showed a 32% incidence of
pre-engraftment BSIsand donor type did not affect their
occurrence·VIsare common in early...


Even at low doses, nivolumab maintenance after allo-SCT can cause
serious immune-related toxicitiesWe report rapid, unexpected
occurrences of grade 3/4 immune-related adverse events ·Nivolumab
enhanced the graft-vs-tumor response but more studies are needed to
improve tolerability
Presenter: Prof.Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr
Vadratsikas


